info@seagull-health.com
SeagullHealth
search
Pirtobrutinib(Jaypirca)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Jaypirca(Pirtobrutinib) Instructions:Uses,Dosage, Side Effects
JAYPIRCA, with the generic name pirtobrutinib, is an orally administered kinase inhibitor. Its active pharmaceutical ingredient targets Bruton's tyrosine kinase (BTK), including both wild-type and C481-mutated forms. It is formulated as film-coated tablets designed for oral ingestion, functioning as a small molecule, noncovalent BTK inhibitor that modulates B-cell receptor signaling pathways crucial for B-cell proliferation and survival.
Adult patients with relapsed or refractory MCL after at least two prior systemic therapies, including a BTK inhibitor.
Adult patients with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
These indications are approved under accelerated approval based on response rate.
Recommended dose: 200 mg orally once daily.
May be taken with or without food. Tablets must be swallowed whole with water; not to be cut, crushed, or chewed.
Dose modifications are required for severe renal impairment (eGFR 15–29 mL/min), concomitant use with strong CYP3A inhibitors or moderate CYP3A inducers, and in case of adverse reactions.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
